Sorrento Therapeutics, Inc. (0L85)の価格はいくらですか

Sorrento Therapeutics, Inc. (0L85)の価格は$0.0033です

Sorrento Therapeutics, Inc. (0L85)の時価総額は何ですか

Sorrento Therapeutics, Inc. (0L85)の時価総額は$1.79Mです

Sorrento Therapeutics, Inc.（0L85）PER（株価収益率）

Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both clinical development and commercialization, dedicated to creating treatments across a broad spectrum of illnesses, including cancer, autoimmune conditions, inflammatory disorders, viral infections, and neurodegenerative diseases. The company conducts its operations through two distinct divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library alongside sophisticated targeted delivery methods. These include chimeric and dimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates, and bispecific antibody strategies. Additionally, its Sofusa drug delivery system enables the direct administration of biologics into the lymphatic system. Sorrento's pipeline features several clinical-stage programs. These encompass an anti-CD38 CAR-T therapy targeting multiple myeloma, amyloidosis, and graft-versus-host disease. The company is also advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, for managing pain associated with late-stage cancer and osteoarthritis of the knee. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. In the realm of pain management, SEMDEXA, an injectable viscous gel, is undergoing Phase III trials for sciatica (a form of lower back pain); SP-103, an experimental non-aqueous lidocaine topical system, is being developed for chronic low back pain; and SP-104 is a novel, low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. The company maintains several strategic collaborations, including a partnership with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical trial involving up to 94 COVID-19 patients. Additionally, Sorrento works with Mount Sinai Health System on COVI-SHIELD, an antibody treatment for SARS-CoV-2 infection, and with Mayo Clinic on a Phase Ib pilot study utilizing Sofusa technology for Ipilimumab delivery in melanoma patients. Established in 2006, Sorrento Therapeutics operates from its headquarters in San Diego, California.

年	P/E比率	変化
提供された日付のデータは十分ではありません。

年

P/E比率

変化

提供された日付のデータは十分ではありません。

企業	P/E比率	P/E比率の差	国
Royalty Pharma plc RPRX.US	24.32	-	US
Swedish Orphan Biovitrum AB SOBI.ST	-	-	SE
Ipsen S.A. IPN.PA	-	-	FR
Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI	-	-	IT
Corcept Therapeutics Incorporated CORT.US	220.13	-	US

企業

P/E比率

P/E比率の差

国